TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Hold” by Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned a consensus rating of “Hold” from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $134.00.

Several equities analysts have commented on TMDX shares. UBS Group reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Stifel Nicolaus dropped their target price on shares of TransMedics Group from $85.00 to $75.00 and set a “hold” rating on the stock in a research report on Tuesday, May 26th. TD Cowen dropped their target price on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Needham & Company LLC dropped their target price on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently modified their holdings of TMDX. Kensington Investment Counsel LLC bought a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $1,926,000. Fieldview Capital Management LLC bought a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $1,716,000. Citigroup Inc. raised its holdings in shares of TransMedics Group by 29.3% in the 3rd quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock worth $8,615,000 after purchasing an additional 17,414 shares during the period. Fred Alger Management LLC raised its holdings in shares of TransMedics Group by 303.8% in the 3rd quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock worth $16,913,000 after purchasing an additional 113,408 shares during the period. Finally, Envestnet Asset Management Inc. raised its position in shares of TransMedics Group by 78.9% in the third quarter. Envestnet Asset Management Inc. now owns 47,048 shares of the company’s stock valued at $5,279,000 after purchasing an additional 20,750 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $69.43 on Tuesday. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 15.78 and a beta of 1.91. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The firm’s 50-day simple moving average is $88.78 and its 200 day simple moving average is $116.94.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same period in the previous year, the business posted $0.70 EPS. TransMedics Group’s revenue was up 21.2% compared to the same quarter last year. As a group, research analysts anticipate that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.